Nanodrugs Targeting T Cells in Tumor Therapy.
CAR-T cell
T cell
immunotherapy
mRNA
melanoma
nanodrug
nanoparticle
regulatory T cell
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
04
2022
accepted:
27
04
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
15
6
2022
Statut:
epublish
Résumé
In contrast to conventional anti-tumor agents, nano-carriers allow co-delivery of distinct drugs in a cell type-specific manner. So far, many nanodrug-based immunotherapeutic approaches aim to target and kill tumor cells directly or to address antigen presenting cells (APC) like dendritic cells (DC) in order to elicit tumor antigen-specific T cell responses. Regulatory T cells (Treg) constitute a major obstacle in tumor therapy by inducing a pro-tolerogenic state in APC and inhibiting T cell activation and T effector cell activity. This review aims to summarize nanodrug-based strategies that aim to address and reprogram Treg to overcome their immunomodulatory activity and to revert the exhaustive state of T effector cells. Further, we will also discuss nano-carrier-based approaches to introduce tumor antigen-specific chimeric antigen receptors (CAR) into T cells for CAR-T cell therapy which constitutes a complementary approach to DC-focused vaccination.
Identifiants
pubmed: 35693776
doi: 10.3389/fimmu.2022.912594
pmc: PMC9174908
doi:
Substances chimiques
Antigens, Neoplasm
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
912594Informations de copyright
Copyright © 2022 Haist, Mailänder and Bros.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nano Lett. 2022 Jan 12;22(1):533-542
pubmed: 34669421
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Oncoimmunology. 2015 May 7;4(8):e1026529
pubmed: 26405584
Nature. 2020 Sep;585(7823):107-112
pubmed: 32728218
J Transl Med. 2012 Aug 03;10:156
pubmed: 22862954
ACS Nano. 2017 Mar 28;11(3):3089-3100
pubmed: 28231431
Nano Lett. 2020 Mar 11;20(3):1578-1589
pubmed: 31951421
Sci Transl Med. 2017 Nov 8;9(415):
pubmed: 29118259
Nano Lett. 2019 May 8;19(5):2774-2783
pubmed: 30943039
Mol Ther. 2016 Jun;24(6):1135-1149
pubmed: 27019998
Cell Death Differ. 2019 Mar;26(4):715-727
pubmed: 30737475
Cells. 2020 Sep 15;9(9):
pubmed: 32942725
Nat Rev Clin Oncol. 2014 Sep;11(9):509-24
pubmed: 25001465
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Cancers (Basel). 2019 Nov 13;11(11):
pubmed: 31766201
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
Int J Nanomedicine. 2020 Aug 13;15:6069-6084
pubmed: 32884263
Biomaterials. 2022 Feb;281:121341
pubmed: 34995901
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Immunology. 2019 Jul;157(3):232-247
pubmed: 31087644
Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13428-13436
pubmed: 32493746
Eur J Clin Invest. 2017 Feb;47(2):184-192
pubmed: 28024097
Anticancer Res. 2013 Aug;33(8):3407-13
pubmed: 23898112
Mol Immunol. 2018 Jun;98:13-18
pubmed: 29525074
Gynecol Oncol. 2020 Oct;159(1):72-78
pubmed: 32771276
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Biomaterials. 2021 Mar;270:120709
pubmed: 33581608
Oncol Lett. 2018 Jul;16(1):687-702
pubmed: 29963134
Sci Rep. 2016 Sep 22;6:33808
pubmed: 27654170
Eur J Pharm Biopharm. 2015 Jan;89:300-11
pubmed: 25500283
J Clin Oncol. 2009 Dec 1;27(34):5763-71
pubmed: 19884534
Future Oncol. 2018 Sep;14(21):2103-2113
pubmed: 29584456
Cancer Res. 2015 Jun 15;75(12):2405-10
pubmed: 25998620
Sci Rep. 2016 Jul 06;6:28709
pubmed: 27381215
Front Immunol. 2019 Feb 04;10:115
pubmed: 30778354
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33785610
Semin Immunol. 2021 Aug;56:101541
pubmed: 34922816
Clin Cancer Res. 2002 Feb;8(2):413-8
pubmed: 11839657
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
ACS Appl Mater Interfaces. 2016 Jun 22;8(24):15086-92
pubmed: 27245481
J Immunol. 1988 Dec 1;141(11):3868-74
pubmed: 3263438
J Clin Oncol. 2013 Jul 1;31(19):2413-20
pubmed: 23715572
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Int J Cancer. 2021 Nov 1;149(9):1628-1638
pubmed: 34224592
J Sep Sci. 2020 May;43(9-10):1978-1997
pubmed: 32077620
Science. 2020 Jan 24;367(6476):446-453
pubmed: 31896660
Sci Rep. 2017 Jul 19;7(1):5790
pubmed: 28724939
Cancer Res. 2013 Jun 1;73(11):3371-80
pubmed: 23633494
Mol Ther. 2013 Aug;21(8):1570-8
pubmed: 23799535
J Control Release. 2016 Jun 10;231:17-28
pubmed: 26829099
Lancet Oncol. 2019 Aug;20(8):1148-1159
pubmed: 31296491
J Control Release. 2018 Jul 10;281:84-96
pubmed: 29777794
Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):285-291
pubmed: 31871161
Nature. 2016 Jun 01;534(7607):396-401
pubmed: 27281205
Int J Mol Sci. 2020 Feb 19;21(4):
pubmed: 32092981
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Oncoimmunology. 2020 Aug 23;9(1):1806680
pubmed: 32923171
Phys Chem Chem Phys. 2020 Dec 23;22(48):28256-28268
pubmed: 33295352
Cancer Res. 2014 Jan 1;74(1):104-18
pubmed: 24197130
ACS Appl Mater Interfaces. 2021 Apr 14;13(14):16007-16018
pubmed: 33797875
Front Oncol. 2021 Sep 16;11:758143
pubmed: 34604097
Curr Top Microbiol Immunol. 2019;423:95-118
pubmed: 30790078
J Clin Oncol. 2005 Nov 1;23(31):7794-803
pubmed: 16172456
Cancer Gene Ther. 2022 Jun;29(6):814-824
pubmed: 34341501
Oncotarget. 2021 May 11;12(10):967-981
pubmed: 34012510
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Nanoscale. 2016 Apr 21;8(15):8255-65
pubmed: 27031090
Biomaterials. 2005 Oct;26(29):5898-906
pubmed: 15949555
Nanomedicine. 2018 Feb;14(2):237-246
pubmed: 29127039
Mol Ther. 2021 Nov 3;29(11):3293-3304
pubmed: 34091054
J Magn Magn Mater. 2022 Jan 1;541:
pubmed: 34720339
Biomaterials. 2021 Dec;279:121184
pubmed: 34678650
J Allergy Clin Immunol. 2013 Sep;132(3):713-722.e11
pubmed: 23791505
Drugs. 2020 Apr;80(6):601-607
pubmed: 32248356
Nanomicro Lett. 2021 Jan 4;13(1):31
pubmed: 34138236
Carbohydr Polym. 2018 Feb 1;181:841-850
pubmed: 29254044
J Cell Mol Med. 2022 Feb;26(3):940-944
pubmed: 35014164
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Sci Transl Med. 2011 Apr 27;3(80):80ra34
pubmed: 21525398
Int J Mol Sci. 2020 Nov 07;21(21):
pubmed: 33171818
Biomacromolecules. 2019 Jan 14;20(1):375-388
pubmed: 30475598
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Nano Lett. 2017 Oct 11;17(10):6110-6116
pubmed: 28876947
Nanomaterials (Basel). 2019 Jan 28;9(2):
pubmed: 30696033
Antib Ther. 2020 Dec;3(4):271-284
pubmed: 33644685
Nat Rev Cancer. 2016 Aug 23;16(9):566-81
pubmed: 27550819
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
Blood. 2007 Dec 15;110(13):4165-71
pubmed: 17846226
J Clin Oncol. 2005 Sep 20;23(27):6674-81
pubmed: 16170175
Int J Mol Sci. 2021 Mar 11;22(6):
pubmed: 33799879
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
ACS Nano. 2019 Oct 22;13(10):11008-11021
pubmed: 31503443
ACS Nano. 2018 Nov 27;12(11):10843-10854
pubmed: 30346692
ACS Nano. 2017 Jun 27;11(6):5417-5429
pubmed: 28589725
Int J Nanomedicine. 2020 Jan 23;15:483-495
pubmed: 32158206
ACS Nano. 2016 Oct 25;10(10):9216-9226
pubmed: 27723299
Int J Nanomedicine. 2020 Mar 10;15:1677-1691
pubmed: 32214807
Nano Lett. 2017 Feb 8;17(2):821-826
pubmed: 28122453
ACS Nano. 2015 Jul 28;9(7):6706-16
pubmed: 26042619
Front Oncol. 2020 Jul 07;10:1000
pubmed: 32733795
Nat Med. 2019 Sep;25(9):1341-1355
pubmed: 31501612
Pharmaceutics. 2021 Dec 06;13(12):
pubmed: 34959378
Biomaterials. 2022 Feb;281:121339
pubmed: 35078042
J Allergy Clin Immunol. 2018 Nov;142(5):1558-1570
pubmed: 29382591
Med Oncol. 2017 Sep;34(9):151
pubmed: 28756613
Cancer Res. 2017 Apr 15;77(8):2040-2051
pubmed: 28235763
Adv Mater. 2018 Jul;30(28):e1801527
pubmed: 29786888
Cancers (Basel). 2020 Dec 15;12(12):
pubmed: 33333816
Lancet Oncol. 2016 Jun;17(6):822-835
pubmed: 27132212
Cancer Immunol Immunother. 2009 Apr;58(4):615-28
pubmed: 18802696
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
J Mater Chem B. 2017 Jun 21;5(23):4410-4415
pubmed: 28966791
Nano Lett. 2021 Feb 24;21(4):1591-1598
pubmed: 33560851
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Clin Cancer Res. 2001 Oct;7(10):3025-30
pubmed: 11595690
AAPS J. 2019 May 17;21(4):64
pubmed: 31102154
J Transl Med. 2020 Jul 3;18(1):269
pubmed: 32620163
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33430105
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
J Clin Invest. 2010 Apr;120(4):1111-24
pubmed: 20234093
AAPS J. 2021 Mar 14;23(2):43
pubmed: 33718979
J Transl Med. 2020 Jun 23;18(1):252
pubmed: 32576225
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Cell Immunol. 2010;263(1):79-87
pubmed: 20346445
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancers (Basel). 2021 Mar 18;13(6):
pubmed: 33803762
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35101971
Cells. 2021 Jun 09;10(6):
pubmed: 34207884
Neoplasia. 2015 Aug;17(8):661-70
pubmed: 26408258
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Nanomedicine. 2012 Nov;8(8):1345-54
pubmed: 22406186
Acta Biomater. 2019 Dec;100:338-351
pubmed: 31586726
Biomacromolecules. 2020 Jun 8;21(6):2473-2481
pubmed: 32383874
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
Ann Oncol. 2004 Mar;15(3):440-9
pubmed: 14998846
Blood Rev. 2018 Nov;32(6):480-489
pubmed: 29709247
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Nano Lett. 2018 Sep 12;18(9):5899-5904
pubmed: 30088769
Cells. 2020 Sep 07;9(9):
pubmed: 32906726
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
Crit Rev Food Sci Nutr. 2018 Jan 2;58(1):70-83
pubmed: 26479307
Mol Ther. 2019 Apr 10;27(4):710-728
pubmed: 30846391
Cancers (Basel). 2021 Aug 17;13(16):
pubmed: 34439296
Cancer Cell. 2015 Jan 12;27(1):12-4
pubmed: 25584891
Lancet Oncol. 2014 Jan;15(1):59-68
pubmed: 24331154
Small. 2022 Mar;18(9):e2105118
pubmed: 34915595
Acta Pharm Sin B. 2021 May;11(5):1129-1147
pubmed: 34094824
Biomater Sci. 2018 Dec 18;7(1):113-124
pubmed: 30444251
Vaccine. 2007 Oct 10;25(41):7145-52
pubmed: 17719152
J Immunol Res. 2021 Mar 27;2021:6644685
pubmed: 33855089
ACS Nano. 2021 Sep 28;15(9):15191-15209
pubmed: 34431291
Acc Chem Res. 2019 Jun 18;52(6):1543-1554
pubmed: 31120725
Transplant Direct. 2017 Jul 19;3(8):e199
pubmed: 28795150
Oncoimmunology. 2019 Jul 11;8(9):e1629259
pubmed: 31428528
Front Immunol. 2018 Aug 02;9:1760
pubmed: 30116246
Mol Ther Oncolytics. 2021 Dec 09;24:148-159
pubmed: 35024441
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Nanomedicine (Lond). 2015;10(7):1063-76
pubmed: 25929565
J Clin Oncol. 2016 Nov 1;34(31):3787-3795
pubmed: 27269940
Angew Chem Int Ed Engl. 2020 Nov 2;59(45):20083-20089
pubmed: 32662132
J Immunol. 1989 Aug 15;143(4):1283-9
pubmed: 2545785
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Nat Biomed Eng. 2018 Jun;2(6):377-391
pubmed: 31011197
J Cell Physiol. 2019 Aug;234(10):18262-18271
pubmed: 30883749
Curr Med Chem. 2020;27(13):2189-2219
pubmed: 30295183
Nano Lett. 2013 Nov 13;13(11):5090-7
pubmed: 24111628
Nanoscale. 2021 Mar 4;13(8):4420-4431
pubmed: 33616147
Clin Transl Immunology. 2016 May 20;5(5):e85
pubmed: 27350884
Cells. 2020 Feb 01;9(2):
pubmed: 32024193
ACS Biomater Sci Eng. 2022 Feb 14;8(2):722-733
pubmed: 35104103